title: [A 3-year-follow-up study on the prognosis of 'two-route chemotherapy' on liver cancer patients with portal vein tumor thrombus].
abstract: OBJECTIVE
  To study the achievements and safety of Transcatheter arterial chemoembolization (TACE) associated Portal Vein Chemo-therapy (PVC) per-drug delivery system (DDS) program in preventing the recurrence of hepatic cell cancer (HCC) and Portal Vein Tumor Thrombus (PVTT).
  
  
  METHODS
  97 cases with HCC and PVTT were treated from January 2009 to January 2011. Patients with tumor or tumor thrombus were resected on all the cases and randomly divided into 3 groups. TACE, PVC per-DDS TACE and PVC per-DDS were given to group A, group B, and group C, respectively. Patients in the 3 groups were followed and compared on the Disease Free Survivals (DFS) and the accumulative survival rates, at 6 months, 1 year and 2 years after the operation.
  
  
  RESULTS
  After the surgery was completed in June, the 1-year, 2-year, 3-year survival rates and cumulative survival rate in group C was higher than in group A or group. Significant differences did not appear in June but did show in 1 year after the surgery (P > 0.05) as well as in both 2 and 3 years, after the surgery (P < 0.01).
  
  
  CONCLUSIONS
  Patients with HCC and PVTT, the TACE chemotherapy in association with PVC per-DDS could increase both the DFSs and accumulative survival rates, when compared to the either single TACE or PVC per-DDS, after the tumor or tumor thrombus were resected.
authors.affiliation: Department of General Surgery, Weihai Municipal Hospital, Weihai, China.
authors.forename: Huan-hu
authors.initials: HH
authors.lastname: Zhang
authors.forename: Sheng-bo
authors.initials: SB
authors.lastname: Sun
authors.forename: Chuan-ji
authors.initials: CJ
authors.lastname: Han
authors.forename: Shao-wei
authors.initials: SW
authors.lastname: Sun
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000188:drug therapy*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating; D011169:Portal Vein; D011379:Prognosis; D016896:Treatment Outcome